Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.88
+0.07 (0.51%)
Mar 6, 2026, 4:00 PM EST - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 10 or 32.26% compared to the previous year.
Employees
41
Change (1Y)
10
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,462,878
Market Cap
507.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 265 |
| Allogene Therapeutics | 229 |
| Prothena Corporation | 163 |
| Invivyd | 100 |
| Solid Biosciences | 100 |
| Neumora Therapeutics | 95 |
| CorMedix | 65 |
| Lexeo Therapeutics | 61 |
CTNM News
- 2 days ago - Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 4 days ago - Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
- 17 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 3 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 3 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
- 3 months ago - Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire